{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:02:54Z","timestamp":1793106174854,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.eururo.2024.10.024","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T02:04:55Z","timestamp":1731722695000},"page":"342-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"87","author":[{"given":"Kwanghee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed M.","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Katims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Lenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Gokturk Ozcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Firouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Elhanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N.","family":"Clinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Aulitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Almassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoich","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Tracey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Reisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadna","family":"Budhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Eichholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Jun","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhi P.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avigdor","family":"Scherz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Aggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene J.","family":"Pietzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman","family":"Seshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oguz","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopa","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Ari","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Merghoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.10.024_b0005","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","article-title":"European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update","volume":"68","author":"Roupret","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.10.024_b0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2024.10.024_b0015","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.10.024_b0020","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.10.024_b0025","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.10.024_b0030","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.10.024_b0035","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular classification and diagnostics of upper urinary tract urothelial carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2024.10.024_b0040","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.024_b0045","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2023.41.6_suppl.511","article-title":"Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC)","volume":"41","author":"Teo","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.024_b0050","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2024.10.024_b0055","article-title":"Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data","volume":"2017","author":"Middha","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2024.10.024_b0060","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2024.10.024_b0065","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1471-2105-11-367","article-title":"A flexible R package for nonnegative matrix factorization","volume":"11","author":"Gaujoux","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.eururo.2024.10.024_b0075","article-title":"Genomic characterization of upper-tract urothelial carcinoma in patients with Lynch syndrome","volume":"2018","author":"Donahue","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2024.10.024_b0080","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2024.42.4_suppl.536","article-title":"Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma","volume":"42","author":"Alam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.024_b0085","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrurol.2011.92","article-title":"Expression of p53 in upper urinary tract urothelial carcinoma","volume":"8","author":"Mitchell","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2024.10.024_b0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13073-020-0721-z","article-title":"Large-scale public data reuse to model immunotherapy response and resistance","volume":"12","author":"Fu","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.eururo.2024.10.024_b0095","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2024.10.024_b0100","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.eururo.2024.10.024_b0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2024.10.024_b0110","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.immuni.2022.10.002","article-title":"Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer","volume":"55","author":"Nixon","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.eururo.2024.10.024_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104452","article-title":"An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers","volume":"88","author":"Mezheyeuski","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.eururo.2024.10.024_b0120","article-title":"Immune cytolytic activity for comprehensive insights of the immune landscape in endometrial carcinoma","volume":"2022","author":"Chen","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.eururo.2024.10.024_b0125","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1002\/cam4.3828","article-title":"Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer","volume":"10","author":"Hu","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.eururo.2024.10.024_b0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2024.10.024_b0135","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000974","article-title":"Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma","volume":"8","author":"Thompson","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eururo.2024.10.024_b0140","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.10.024_b0145","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","article-title":"Elevated T-cell exhaustion and urinary tumor DNA levels are associated with bacillus Calmette-Guerin failure in patients with non-muscle-invasive bladder cancer","volume":"82","author":"Strandgaard","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.10.024_b0150","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.10.024_b0155","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.10.024_b0160","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.12363","article-title":"Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial","volume":"10","author":"Griffin","year":"2024","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.eururo.2024.10.024_b0165","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/curroncol29020060","article-title":"Current advances in immune checkpoint inhibition and clinical genomics in upper tract urothelial carcinoma: state of the art","volume":"29","author":"Califano","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.eururo.2024.10.024_b0170","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.10.024_b0175","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000360227","article-title":"p53 expression as a prognostic factor in upper urinary tract urothelial carcinoma: a systematic review and meta-analysis","volume":"94","author":"Lee","year":"2015","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2024.10.024_b0180","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.024_b0185","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","article-title":"Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience","volume":"125","author":"Rose","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2024.10.024_b0190","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2024.10.024_b0195","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1038\/s41467-024-46320-w","article-title":"The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis","volume":"15","author":"Ohara","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.10.024_b0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.024_b0205","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.024_b0210","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/onc.2010.292","article-title":"Extracellular adenosine triphosphate and adenosine in cancer","volume":"29","author":"Stagg","year":"2010","journal-title":"Oncogene"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824026861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824026861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T22:58:33Z","timestamp":1739833113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824026861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0302283824026861"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.10.024","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}